News & Updates

Show Multimedia Only
10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

25 Aug 2026 byNatalia Reoutova

A phase II study of patients with heavily pretreated B-cell non-Hodgkin lymphoma (NHL) reports decade-long remissions in approximately one-third of patients with large B-cell lymphomas (LBCL) and in nearly half of patients with follicular lymphoma (FL), following a single infusion of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel.

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

25 Aug 2026